SNY:NYE-Sanofi American Depositary Shares (Each repstg one-half of one) (USD)

EQUITY | Drug Manufacturers - General | New York Stock Exchange

Last Closing

USD 57.63

Change

-0.02 (-0.03)%

Market Cap

USD 100.27B

Volume

1.33M

Analyst Target

USD 56.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.29 (+0.37%)

USD 241.92B
AMGN Amgen Inc

-0.46 (-0.14%)

USD 173.38B
GILD Gilead Sciences Inc

+0.23 (+0.28%)

USD 104.09B
BIIB Biogen Inc

-0.83 (-0.43%)

USD 28.36B
GRFS Grifols SA ADR

-0.07 (-0.78%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.02 (+3.76%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.14 (+12.07%)

USD 0.02B
SCLX Scilex Holding Company

-0.02 (-1.70%)

N/A
SCLXW Scilex Holding Company

-0.04 (-15.38%)

N/A

ETFs Containing SNY

LIFE:CA Evolve Global Healthcare .. 5.09 % 0.69 %

+0.12 (+0.00%)

CAD 0.21B
HVAX:CA 4.85 % 0.00 %

N/A

N/A
PINK Simplify Exchange Traded .. 4.75 % 0.00 %

+0.09 (+0.00%)

USD 0.24B
SEUC:PA SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

+0.01 (+0.00%)

USD 1.16B
SYBD:F SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

+0.01 (+0.00%)

USD 1.16B
SYBD:XETRA SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

+0.01 (+0.00%)

USD 1.27B
SEUC:SW SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

N/A

USD 1.15B
ADRD 0.00 % 0.26 %

N/A

N/A
ADRU 0.00 % 0.30 %

N/A

N/A
EUR:CA 0.00 % 0.66 %

N/A

N/A
PPH VanEck Pharmaceutical ETF 0.00 % 0.36 %

+0.19 (+0.00%)

USD 0.72B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
SANE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.89% 85% B 74% C
Dividend Return 4.10% 88% B+ 76% C+
Total Return 19.98% 85% B 77% C+
Trailing 12 Months  
Capital Gain 7.56% 65% D 53% F
Dividend Return 3.80% 88% B+ 56% F
Total Return 11.36% 65% D 54% F
Trailing 5 Years  
Capital Gain 30.24% 50% F 63% D
Dividend Return 21.63% 90% A- 80% B-
Total Return 51.87% 50% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 1.22% N/A N/A 46% F
Dividend Return 5.01% N/A N/A 54% F
Total Return 3.79% N/A N/A 75% C
Risk Return Profile  
Volatility (Standard Deviation) 11.32% N/A N/A 86% B+
Risk Adjusted Return 44.23% N/A N/A 74% C
Market Capitalization 100.27B 69% C- 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.70 79% 31%
Price/Book Ratio 1.77 69% 52%
Price / Cash Flow Ratio 14.12 69% 21%
Price/Free Cash Flow Ratio 13.56 56% 26%
Management Effectiveness  
Return on Equity 5.82% 56% 69%
Return on Invested Capital 8.23% 56% 75%
Return on Assets 4.16% 44% 83%
Debt to Equity Ratio 19.38% 92% 62%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector